(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 June 2010 (03.06.2010)

PCT

(10) International Publication Number
WO 2010/060486 A1

(51) International Patent Classification:
C07K 16/24 (2006.01) *A61P 11/00* (2006.01)

(21) International Application Number:
PCT/EP2008/067789

(22) International Filing Date:
17 December 2008 (17.12.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/118,013 26 November 2008 (26.11.2008) US

(71) Applicants *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB). **DOMANTIS LIMITED** [GB/GB]; 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DE WILDT, Rudolf, M, T** [NL/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge Cambridgeshire CB4 0WG (GB). **DE SILVA, Inusha** [GB/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge Cambridgeshire CB4 0WG (GB). **OVECKA, Milan** [SK/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge Cambridgeshire CB4 0WG (GB).

(74) Agents: **CLUBE, Jasper, Rupert** et al.; GlaxoSmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

WO 2010/060486 A1

(54) Title: LIGANDS THAT BIND IL-13

(57) Abstract: Disclosed are ligands that have binding specificity for interleukin-13 (IL-13), or for IL-4 and IL- 13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating IL-13-mediated conditions, such as lung conditions, eg allergic asthma, is described. The ligands have potent IL-13 binding kinetics. Ligands are described that are cross-reactive between human IL- 13 and one or more primate IL-13. Ligands are well expressed in prokaryotic cells.